Jasper Therapeutics to Present Data on Briquilimab in Mast C

REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting

Related Keywords

Granada , Andalucísp , Spain , Valencia , Carabobo , Venezuela , United States , Lauren Walker , Alex Gray , Joyce Allaire , Edwin Tucker , European Academy Of Allergy , Jasper Therapeutics Inc , Single Subcutaneous Sc Administration To Healthy , European Academy , Clinical Immunology , Kit Mouse , Wendy Pang , Senior Vice President , Translational Medicine , Chief Medical Officer , Dose Escalation Study , Preliminary Clinical Activity , Kit Mab Briquilimab , Chronic Spontaneous Urticaria , Oral Abstract , Chronic Urticaria , Mice Expressing Chimeric , Flash Talks , Allergic Response , Single Subcutaneous , Healthy Male , Epithelial Cell , Dose Escalation Trial , Adult Patients , Chronic Inducible Urticaria , Who Remain Symptomatic Despite Treatment , Mouse Model Expressing Chimeric , Cutting Edge Mastocytosis , Jasper Therapeutics , Annual Report , Quarterly Reports ,